| Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease TR Sampson, JW Debelius, T Thron, S Janssen, GG Shastri, ZE Ilhan, ... Cell 167 (6), 1469-1480. e12, 2016 | 3498 | 2016 |
| Unified Huntington's disease rating scale: reliability and consistency K Kieburtz, JB Penney, P Como, N Ranen, I Shoulson, A Feigin, ... Movement disorders 11 (2), 136-142, 1996 | 2069 | 1996 |
| A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease CW Olanow, CG Goetz, JH Kordower, AJ Stoessl, V Sossi, MF Brin, ... Annals of neurology 54 (3), 403-414, 2003 | 1926 | 2003 |
| Colonic bacterial composition in Parkinson's disease A Keshavarzian, SJ Green, PA Engen, RM Voigt, A Naqib, CB Forsyth, ... Movement Disorders 30 (10), 1351-1360, 2015 | 1343 | 2015 |
| Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease CB Forsyth, KM Shannon, JH Kordower, RM Voigt, M Shaikh, JA Jaglin, ... PloS one 6 (12), e28032, 2011 | 963 | 2011 |
| Prevalence of parkinsonian signs and associated mortality in a community population of older people DA Bennett, LA Beckett, AM Murray, KM Shannon, CG Goetz, DM Pilgrim, ... New England Journal of Medicine 334 (2), 71-76, 1996 | 921 | 1996 |
| A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study Parkinson Study Group Archives of Neurology 59 (12), 1937-1943, 2002 | 704 | 2002 |
| Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review):[RETIRED] Report of the Quality Standards … JM Miyasaki, K Shannon, V Voon, B Ravina, G Kleiner-Fisman, ... Neurology 66 (7), 996-1002, 2006 | 702 | 2006 |
| Alpha‐synuclein in colonic submucosa in early untreated Parkinson's disease KM Shannon, A Keshavarzian, E Mutlu, HB Dodiya, D Daian, JA Jaglin, ... Movement Disorders 27 (6), 709-715, 2012 | 519 | 2012 |
| Is alpha‐synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases KM Shannon, A Keshavarzian, HB Dodiya, S Jakate, JH Kordower Movement Disorders 27 (6), 716-719, 2012 | 515 | 2012 |
| CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion JM Lee, EM Ramos, JH Lee, T Gillis, JS Mysore, MR Hayden, SC Warby, ... Neurology 78 (10), 690-695, 2012 | 455 | 2012 |
| Role of TLR4 in the gut-brain axis in Parkinson’s disease: a translational study from men to mice P Perez-Pardo, HB Dodiya, PA Engen, CB Forsyth, AM Huschens, ... Gut 68 (5), 829-843, 2019 | 424 | 2019 |
| A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease IH Richard, MP McDermott, R Kurlan, JM Lyness, PG Como, N Pearson, ... Neurology 78 (16), 1229-1236, 2012 | 404 | 2012 |
| Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease KM Shannon, JP Bennett Jr, JH Friedman, Pramipexole Study Group Neurology 49 (3), 724-728, 1997 | 404 | 1997 |
| Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results JS Fink, JM Schumacher, SL Ellias, EP Palmer, M Saint-Hilaire, ... Cell transplantation 9 (2), 273-278, 2000 | 329 | 2000 |
| Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease CG Goetz, CW Olanow, WC Koller, RD Penn, D Cahill, R Morantz, ... New England Journal of Medicine 320 (6), 337-341, 1989 | 317 | 1989 |
| Progression of intestinal permeability changes and alpha‐synuclein expression in a mouse model of Parkinson's disease LP Kelly, PM Carvey, A Keshavarzian, KM Shannon, M Shaikh, ... Movement Disorders 29 (8), 999-1009, 2014 | 308 | 2014 |
| Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia CL Comella, J Jankovic, KM Shannon, J Tsui, M Swenson, S Leurgans, ... Neurology 65 (9), 1423-1429, 2005 | 292 | 2005 |
| Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease HB Dodiya, CB Forsyth, RM Voigt, PA Engen, J Patel, M Shaikh, SJ Green, ... Neurobiology of disease 135, 104352, 2020 | 268 | 2020 |
| An R5L τ mutation in a subject with a progressive supranuclear palsy phenotype P Poorkaj, NA Muma, V Zhukareva, EJ Cochran, KM Shannon, H Hurtig, ... Annals of Neurology: Official Journal of the American Neurological …, 2002 | 264 | 2002 |
